US Patent

US11759497 — Daptomycin formulations

Formulation · Assigned to Xellia Pharmaceuticals ApS · Expires 2038-08-28 · 12y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of daptomycin, specifically those including at least one amino acid, according to Xellia Pharmaceuticals ApS.

USPTO Abstract

The present invention relates to compositions comprising daptomycin and at least one amino acid, methods of providing such compositions and the uses thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11759497
Jurisdiction
US
Classification
Formulation
Expires
2038-08-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Xellia Pharmaceuticals ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.